NEJM This Week — April 2, 2026 @NEJMgroup
NEJM This Week — April 2, 2026  @NEJMgroup
Uploaded April 2026 | Updated September 2026, 1 week ago
This week, we present new research on treatment for muscle-invasive bladder cancer, left atrial appendage closure versus medical therapy for atrial fibrillation, gene-editing approaches for sickle cell disease and β-thalassemia, and the safety of discontinuing beta-blockers after myocardial infarction. We also review GLP-1 receptor agonists and discuss a Clinical Problem-Solving case of a man with progressive confusion. Perspectives explore corporatization; biologic, as opposed to chronologic, aging; and a legal case that could affect mental-health policy.
NEJM This Week — April 2, 2026Teclistamab in Previously Treated Multiple Myeloma (MajesTEC-9)NEJM Interview: Jean Nachega on the importance of investment in equitable partnerships, community...Ask the Expert: What’s the H2FPEF Score?Logistic Regression | NEJM EvidenceImage Challenge — July 23, 2026Original Article: Atezolizumab plus FOLFOX for Stage III Colon Cancer (ATOMIC)Dr. Glaucomflecken Explains: Clesrovimab for Prevention of RSV Disease in Healthy Infants (CLEVER)Images in Clinical Medicine: Bronchial Casts from Inhalation of Forest-Fire SmokeClinical Decisions: Operative versus Nonoperative Management for AppendicitisReview Article: GLP-1 Receptor AgonistsNEJM Interview: Raja-Elie Abdulnour on the need for clinicians and AI systems to refrain from exp...
NEJM Group |

NEJM This Week — April 2, 2026

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER